CPT code 0412U designates the PrecivityAD® proprietary blood test from C2N Diagnostics LLC, a laboratory-based assay that quantifies plasma beta-amyloid 40 and 42 and identifies ApoE protein phenotype, producing an algorithmic probability score for cerebral amyloid plaque consistent with Alzheimer’s disease. As a PLA code, 0412U is specific to a single manufacturer’s test and is used for reporting this unique biomarker service nationally. The code matters because blood-based biomarkers are changing diagnostic pathways for Alzheimer’s disease, potentially affecting utilization, coverage policies, and access to diagnostic services.

Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a compact review of what the code represents, expected service settings, and the clinical context for its use. The publication will also summarize payer coverage considerations and benchmarking where available, outline common billing modifiers associated with laboratory and professional components, and note gaps where data are not provided.

The content is written for a national audience and focuses on clinical and billing context rather than state-specific policy. Data not provided in the input is noted as unavailable.